|
|
|
Atossa Therapeutics Inc (NASDAQ: ATOS) |
|
Atossa Therapeutics Inc
Officers & Directors
Atossa Therapeutics Inc. Executives and Directors: - Steven C. Quay Chairman, President, and Chief Executive Officer - Heather Rees Senior Vice President, Finance and Accounting - Richard I. Steinhart Director - Stephen J. Galli Director - Shu-Chih Chen Director - Jonathan Finn Director - Tessa Cigler Director - H. Lawrence Remmel Director ,
Atossa Therapeutics Inc currently has 16 employees.
News about Atossa Therapeutics Inc Key Personnel |
In a dynamic and often challenging landscape for biopharmaceutical innovation, Atossa Therapeutics, Inc. (Nasdaq: ATOS) continues to establish itself as a vanguard in the fight against breast cancer. The Seattle-based company, dedicated to the prevention and treatment of this prevalent malignancy, recently navigated a significant hurdle in the realm of intellectual property while simultaneously advancing promising therapeutic strategies.On January 30, 2025, Atossa Therapeutics responded to a pivotal ruling from the Patent Trial and Appeal Board (PTAB) regarding U.S. Patent No. 11,572,334, or the 334 patent. The final written decision in case PGR2023-00043 emerges from ongoing efforts to protect proprietary ...
|
In a significant development for breast cancer awareness and early detection, the U.S. Food and Drug Administration (FDA) has implemented a final rule mandating patient notifications regarding breast density as part of updated mammography regulations. This move is hailed as a milestone in addressing a crucial risk factor for breast cancer, potentially leading to earlier diagnosis and better outcomes for patients. The rule s effective date aligns with heightened attention on breast density, a known factor that can obscure cancer detection on mammograms and complicate screening efforts.
Atossa Therapeutics Inc. a biopharmaceutical company focused on innovative treatments in the field of breast health,...
|
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company, announced on March 18, 2024, that it has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). This comes after receiving written notice on March 15, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq). The company s focus lies in developing innovative medicines in areas of significant unmet medical need in oncology, particularly in using (Z)-endoxifen to prevent and treat breast cancer.
In the preceding 12 months ending in the third quarte...
|
In our rapidly advancing world of medical research and development, cancer remains one of the most formidable challenges, particularly breast cancer, which continues to affect millions of women worldwide. However, in an era of groundbreaking advancements, pharmaceutical company Atossa Therapeutics, Inc. (Nasdaq: ATOS) is taking great strides in pioneering innovative medicines to combat breast cancer and address unmet medical needs. With an unwavering focus on oncology, Atossa Therapeutics is poised to redefine the landscape of breast cancer treatment.
Under the astute leadership of President and Chief Executive Officer Dr. Steven Quay, Atossa Therapeutics has made significant progress in the field o...
|
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
